Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
Date:5/2/2013

tigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial completion and design and statements regarding the potential benefits and potential development of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product candidates and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

ORCA™, Borealis-1™, Borealis-2™, Spruce™, Rainier™ and Pacific™, are registered trademarks of OncoGenex Pharmaceuticals, Inc.
ABRAXANE® is a registered trademark of Celgene Corporation
JEVTANA® is a registered trademark of sanofi-aventis
Zytiga® is a registered trademark of the Johnson & Johnson Corporation

 


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
3. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
4. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
8. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
9. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
10. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
11. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... affects persons of all ages, but most commonly ... condition characterized by narrowing of the airways, leading ... the lungs come into contact with endogenous and ... of events, such as swelling of the airways, ...
(Date:9/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... owned subsidiary, Valeant Pharmaceuticals International, will redeem all of ... 6.75% Senior Notes due 2017, CUSIP Nos. 91911XAL8, U9098VAD4 ... has mailed an irrevocable notice of redemption for the ... of the irrevocable notice of redemption with respect to ...
(Date:9/15/2014)... , Sept. 15, 2014  Decision Resources ... Physician™ 2014, finds that online information and ... brands to differentiate their offering and support ... device purchasing decisions rely on websites, mobile ... about devices—and these physicians are looking to ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2Physician device decision-makers show strong demand for device manufacturer digital content and support 2Physician device decision-makers show strong demand for device manufacturer digital content and support 3
... NJ, Aug. 18 /PRNewswire-Asia/ -- ... ... var shortURL = ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... On August 9, 2010 Massachusetts passed Chapter 283 ... Prescription Monitoring Program and furthering Substance Abuse Education and ... in Massachusetts that dispense schedule II, III, IV, or ... sale at each location. More info at http://www.mass.gov/legis/laws/seslaw10/sl100283.htm ...
Cached Medicine Technology:Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 2Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 3Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 4Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 5Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 6New Law Requires Pharmacies in Massachusetts to Carry Rx Lock Boxes 2
(Date:9/16/2014)... Hills, CA (PRWEB) September 16, 2014 ... announce the launch of ACLsurgeryLA.com , a specialty ... ACL injuries. As an avid sports lover and ... options for treatment and recovery from injuries to maintain ... opportunity to offer patients a resource dedicated specifically to ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 *To find out ... visit Achieve Clinical Research on the web ( http://www.achieveclinical.com/trial/pneumonia-vaccine/ ) ... who qualify:, There is no cost ... , Compensation may be provided for time and ... and influenza are the eighth leading cause of death in ...
(Date:9/16/2014)... DeLand, Florida (PRWEB) September 16, 2014 ... clinical trials being conducted in DeLand, FL can visit ... or contact them directly at (386) 785-2404. , Why ... of the most widespread viral diseases infecting mankind. While ... past, these colds still account for more annual visits ...
(Date:9/16/2014)... 2014 justthoughtyoushouldknow.org , popular ... launches their new site today. The new site ... at making information easier to find, ingest, and ... into one-page, easy-to-read pages the information that we ... Virginia Downie, retired college professor and founder of ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3Health News:JustThoughtYouShouldKnow.org Debuts New Website 2
... Dec. 6 Arete Therapeutics Inc., a,privately-held biopharmaceutical ... of cardiovascular, inflammatory and,metabolic diseases, today announced the ... directors., "We are very pleased to welcome ... and operational insights will be of great benefit ...
... Name Also Unveiled in Ongoing Preparation for ... Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical company ... cancer, announced that new data,including four-year follow-up ... of Specifid(TM) (formerly FavId(R)), will be reported ...
... Oncology, the nation,s leading,oncology services company, today named ... and chief operating officer. The appointment,becomes effective on ... experience, combined with his work in,large diversified healthcare ... Broussard, president of US Oncology.,"His proven success in ...
... first increase in U.S.,teen pregnancy rates, WASHINGTON, Dec. ... pregnancy rates in the United States over the,last fourteen ... should not come as a surprise since the dual ... -- the decline in sexual,initiation and more effective use ...
... http://feeds.feedburner.com/OrthoWomensHealthAndUrology , RARITAN, NJ, December 5 Jane ... about the Pill as part of The Modern,Girl,s Guide ... Girl,s Guide to the Pill, When: The Podcast ... Where: http://feeds.feedburner.com/OrthoWomensHealthAndUrology , How: Go to ...
... With the popularity of,fillers becoming mainstream, it,s no ... prevent facial wrinkles. Dr. Arnold Klein, world,renowned cosmetic ... "Fillers such as Artefill, Radiesse and Sculptra contain ... tissue, all of,these products can cause foreign body ...
Cached Medicine News:Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 3Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 4Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 5Health News:US Oncology Appoints Glen Laschober EVP & Chief Operating Officer 2Health News:Facial Deformity Danger? 2
...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Medicine Products: